103 related articles for article (PubMed ID: 3988128)
21. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
[TBL] [Abstract][Full Text] [Related]
22. K cell activity in ovarian cancer patients given chemotherapy.
Mantovani A; Polentarutti N; Gritti P; Bolis G; Maggioni A; Spreafico F
Eur J Cancer (1965); 1979 May; 15(5):797-802. PubMed ID: 510340
[No Abstract] [Full Text] [Related]
23. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer.
Trimbos JB; Schueler JA; van der Burg M; Hermans J; van Lent M; Heintz AP; Fleuren GJ
Cancer; 1991 Feb; 67(3):597-602. PubMed ID: 1985754
[TBL] [Abstract][Full Text] [Related]
24. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
[TBL] [Abstract][Full Text] [Related]
25. Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors.
Mantovani A; Allavena P; Sessa C; Bolis G; Mangioni C
Int J Cancer; 1980 May; 25(5):573-82. PubMed ID: 6154662
[TBL] [Abstract][Full Text] [Related]
26. Immune restoration with interleukin-2 in patients with squamous cell carcinoma of the head and neck.
Wanebo HJ; Jones T; Pace R; Cantrell R; Levine P
Am J Surg; 1989 Oct; 158(4):356-60. PubMed ID: 2802041
[TBL] [Abstract][Full Text] [Related]
27. Seminal plasma suppression of human lymphocyte responses in vitro requires the presence of bovine serum factors.
Vallely PJ; Rees RC
Clin Exp Immunol; 1986 Oct; 66(1):181-7. PubMed ID: 3492315
[TBL] [Abstract][Full Text] [Related]
28. The tuberculin reaction in the pleural cavity and its suppression by antilymphocyte serum.
Leibowitz S; Kennedy L; Lessof MH
Br J Exp Pathol; 1973 Apr; 54(2):152-62. PubMed ID: 4700698
[TBL] [Abstract][Full Text] [Related]
29. Evidence of cross-reactivity of 'carcinoma-specific' KC4 monoclonal antibody with activated mesothelial cells and phytohemagglutinin-stimulated lymphocytes.
Neubauer A; Musch R; Thalmann U; Grosser H; Laser J; Loddenkemper R; Huhn D
Oncology; 1988; 45(5):380-3. PubMed ID: 3412748
[TBL] [Abstract][Full Text] [Related]
30. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
31. Association between urinary zinc excretion and lymphocyte dysfunction in patients with lung cancer.
Allen JI; Bell E; Boosalis MG; Oken MM; McClain CJ; Levine AS; Morley JE
Am J Med; 1985 Aug; 79(2):209-15. PubMed ID: 2992269
[TBL] [Abstract][Full Text] [Related]
32. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
33. Immunological variations in women suffering from ovarian cancer. Influence of radical surgical treatment.
Rampone B; Rampone A; Tirabasso S; Panariello S; Rampone N
Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):116-9. PubMed ID: 11526704
[TBL] [Abstract][Full Text] [Related]
34. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.
McGuckin MA; Layton GT; Bailey MJ; Hurst T; Khoo SK; Ward BG
Gynecol Oncol; 1990 May; 37(2):165-71. PubMed ID: 1693126
[TBL] [Abstract][Full Text] [Related]
36. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.
Pupa SM; Canevari S; Fontanelli R; Ménard S; Mezzanzanica D; Lanzavecchia A; Colnaghi MI
Int J Cancer; 1988 Sep; 42(3):455-9. PubMed ID: 2971021
[TBL] [Abstract][Full Text] [Related]
37. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma.
Dong HP; Elstrand MB; Holth A; Silins I; Berner A; Trope CG; Davidson B; Risberg B
Am J Clin Pathol; 2006 Mar; 125(3):451-8. PubMed ID: 16613351
[TBL] [Abstract][Full Text] [Related]
38. The effect of antilymphocyte globulin (ALG) on human lymphocytes in vitro: inhibition of lymphotoxin production as a sensitive indicator for ALG activity.
Eife GW; Eife RF; Brendel W
Cell Immunol; 1979 Aug; 46(1):35-47. PubMed ID: 314848
[No Abstract] [Full Text] [Related]
39. Activation of lymphocytes by PPD and PHA is promoted by exudate from BCG-induced pleurisy.
Widström O
Eur J Respir Dis; 1984 Oct; 65(7):537-43. PubMed ID: 6489488
[TBL] [Abstract][Full Text] [Related]
40. CA 125 in gynecologic practice.
Malkasian GD; Podratz KC; Stanhope CR; Ritts RE; Zurawski VR
Am J Obstet Gynecol; 1986 Sep; 155(3):515-8. PubMed ID: 2428248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
